Laura Panjwani

Tasigna and Mekinist is showing promise for the treatment of patients with BRAF/NRAS wild-type melanoma, according to a recent study.

John P. Leonard, M.D. spoke with CURE about some upcoming advancements in the treatment of follicular lymphoma.

Patients with metastatic colorectal cancer now have more treatment options than ever, explains Tanios Bekaii-Saab, M.D.

Clinical trial enrollment must become speedier for patients with rare diseases such as anaplastic thyroid cancer, says Maria Cabanillas, M.D.

A rock band made up of gynecologic oncologists is connecting with patients and their fans through rock music.

Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.

Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.

Roman Perez-Soler, M.D. discusses the EGFR resistance in non-small cell lung cancer (NSCLC).

Three recently-discovered molecular subtypes may help in crafting a more personalized treatment plan for men with prostate cancer.

Women who were vaccinated against HPV do not need to be screened for cervical cancer as often, according to a recent study.

Tumor-treating fields are having a huge impact on the treatment and outcomes of patients with glioblastoma multiforme (GBM).

Stivarga is being considered by the FDA for approval for second-line liver cancer treatment, renewing hope in the field.

Fewer than half the women with advanced cervical cancer are receiving standard of care.

Treatment advances, including a three-drug combo, are improving outcomes for patients with myeloma.

In an interview with CURE, James Allison, Ph.D. talks about the progress immunotherapy has made, as well as potential combinations with immunotherapy and other treatment types to provide better outcomes for patients.

Treatment and imaging advancements are drastically changing the landscape of sarcoma care.

While colorectal cancer on the left side may have a survival benefit, the stage of the cancer may pay an important role.

CURE spoke with expert Jason Luke about updates and future prospects for immunotherapy in melanoma.

With its series of hikes, Moving Mountains for Multiple Myeloma inspires donations — and pride.

After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh.

Immunotherapy may not end up being as successful in treating sarcoma as it is in other types of cancer, says Katherine Thornton M.D.

The approval of Keytruda for metastatic head and neck squamous cell carcinoma is just the beginning when it comes to treating head and neck cancer with immunotherapy.

Like his signature backflip, Olympic figure skater Scott Hamilton’s vision for supporting patients with cancer is bold and unique.

CURE spoke with David Reardon about immunotherapy and the future of treating brain cancer.

Jedd D. Wolchok discusses the future of immunotherapy in melanoma treatment.

After losing his mother to breast cancer and then fighting testicular cancer himself, Olympic gold medalist Scott Hamilton started a foundation to help those touched by the disease.

A three-drug approach is proving beneficial for the treatment of multiple myeloma.

Charlie Gourley discusses where Lynparza fits in with ovarian cancer care.

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.

Recent years brought many advances in the field of immunotherapy in melanoma, but more still needs to be done.